A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II, randomized, double-blind, placebo-controlled, parallel, multicenter
study of a certain phase to evaluate the efficacy, safety, and pharmacokinetic
characteristics of QY201 tablet in subjects in moderate to severe atopic dermatitis